Protagenic Therapeutics, Inc. (PTIX) 은(는) 상장 기업입니다 헬스케어 섹터의 바이오 산업에서 운영. 본사 소재지는 New York City, NY, 미국. 현재 CEO는 Garo H. Armen.
PTIX 을(를) 보유 IPO 날짜 2021-04-27, 1 명의 정규직 직원, 에 상장 NASDAQ Capital Marke, 시가총액 $1.08M.
Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound is PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. The company is based in New York, New York.
